Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018;8(4):517-527.
doi: 10.3233/JPD-181434.

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)

Lana M Chahine  1 , Thomas G Beach  2 , Nicholas Seedorff  3 , Chelsea Caspell-Garcia  3 , Christopher S Coffey  3 , Michael Brumm  3 , Charles H Adler  4 , Geidy E Serrano  2 , Carly Linder  5 , Sherri Mosovsky  1 , Tatiana Foroud  6 , Holly Riss  3 , Dixie Ecklund  3 , John Seibyl  7 , Danna Jennings  8 , Vanessa Arnedo  9 , Lindsey Riley  9 , K D Dave  9 , Brit Mollenhauer  10 ; Systemic sSynuclein Sampling study
Affiliations

Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4)

Lana M Chahine et al. J Parkinsons Dis. 2018.

Abstract

Background: α-synuclein is a lead Parkinson's disease (PD) biomarker. There are conflicting reports regarding accuracy of α-synuclein in different tissues and biofluids as a PD biomarker, and the within-subject anatomical distribution of α-synuclein is not well described. The Systemic Synuclein Sampling Study (S4) aims to address these gaps in knowledge. The S4 is a multicenter, cross-sectional, observational study evaluating α-synuclein in multiple tissues and biofluids in PD and healthy controls (HC).

Objective: To describe the baseline characteristics of the S4 cohort and safety and feasibility of this study.

Methods: Participants underwent motor and non-motor clinical assessments, dopamine transporter SPECT, biofluid collection (cerebrospinal fluid, saliva, and blood), and tissue biopsies (skin, sigmoid colon, and submandibular gland). Biopsy adequacy was determined based on presence of adequate target tissue. Tissue sections were stained with the 5C12 monoclonal antibody against unmodified α-synuclein. All specimens were acquired and processed in a standardized manner. Adverse events were systematically recorded.

Results: The final cohort consists of 82 participants (61 PD, 21 HC). In 68 subjects (83%), all types of specimens were obtained but only 50 (61%) of subjects had all specimens both collected and evaluable for α-synuclein. Mild adverse events were common, especially for submandibular gland biopsy, but only 1 severe adverse event occurred.

Conclusion: Multicenter tissue and biofluid sampling for α-synuclein is feasible and generally safe. S4 will inform understanding of the concurrent distribution of α-synuclein pathology and biomarkers in biofluids and peripheral nervous system in PD.

Keywords: Biomarkers; Parkinson’s disease; needle biopsy; synucleins.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Steps in tissue processing and assessment of adequacy in S4. Steps for assessments of safety and feasibility are highlighted in grey. AE, adverse event; CRO, contract research organization; FFPE, formalin-fixed paraffin-embedded; H&E, hematoxylin and eosin.
See this image and copyright information in PMC

References

    1. Eriksen JL, Przedborski S, Petrucelli L (2005) Gene dosage and pathogenesis of Parkinson’s disease. Trends Mol Med 11, 91–96. - PubMed
    1. Adler CH, Dugger BN, Hentz JG, Hinni ML, Lott DG, Driver-Dunckley E, Mehta S, Serrano G, Sue LI, Duffy A, Intorcia A, Filon J, Pullen J, Walker DG, Beach TG (2016) Peripheral synucleinopathy in early Parkinson's disease: Submandibular gland needle biopsy findings. Mov Disord 31, 250–256. - PMC - PubMed
    1. Vilas D, Iranzo A, Tolosa E, Aldecoa I, Berenguer J, Vilaseca I, Marti C, Serradell M, Lomena F, Alos L, Gaig C, Santamaria J, Gelpi E (2016) Assessment of alpha-synuclein in submandibular glands of patients with idiopathic rapid-eye-movement sleep behaviour disorder: A case-control study. Lancet Neurol 15, 708–718. - PubMed
    1. Lee JM, Derkinderen P, Kordower JH, Freeman R, Munoz DG, Kremer T, Zago W, Hutten SJ, Adler CH, Serrano GE, Beach TG (2017) The search for a peripheral biopsy indicator of alpha-synuclein pathology for Parkinson disease. J Neuropathol Exp Neurol 76, 2–15. - PubMed
    1. Visanji NP, Mollenhauer B, Beach TG, Adler CH, Coffey CS, Kopil CM, Dave KD, Foroud T, Chahine L, Jennings D, Systemic Synuclein Sampling Study (S4) (2017) The Systemic Synuclein Sampling Study: Toward a biomarker for Parkinson's disease. Biomark Med 11, 359–368. - PubMed

Publication types

LinkOut - more resources